(2026). Treatment Outcomes of Lebrikizumab after Switching from Dupilumab in Moderate-to-Severe Atopic Dermatitis involving the Head and Neck Area. Dermatology and Therapy.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"Treatment Outcomes of Lebrikizumab After Switching from Dupilumab in Moderate-to-Severe Atopic Dermatitis Involving the Head and Neck Area."
Dermatology and Therapy 2026.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"Treatment Outcomes of Lebrikizumab After Switching from Dupilumab in Moderate-to-Severe Atopic Dermatitis Involving the Head and Neck Area."
Dermatology and Therapy, 2026.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.